Amendment to the Specification:

On page 1, please replace the title with following amended title:

— Oxazolidinone Nicotinic Acetylcholine Receptor Agonists —

On page 1, after the title and before the first paragraph, please INSERT

— This is a National Phase filing of International Application No. PCT/GB2004/002904, filed July 6, 2004, which claims the priority of Provisional Application No. 60/485,523 filed in The U.S.A. on July 8, 2003. —

On page 2, please replace line 14 with the following amended line

provided that R^2 is Q at one ~~occurence~~occurrence, and at one occurrence is a bond connecting Ar^1 to

On page 4, please replace line 21 with the following amended line

provided that R^2 is Q at one ~~occurence~~occurrence, and at one occurrence is a bond connecting Ar^1 to

On page 6, please replace line 13 with the following amended line

~~occurence~~occurrence, and at one occurrence is a bond connecting Ar^1 to A, or when -A- is a bond, to

On page 7, please replace line 18 with the following amended line

~~occurence~~occurrence and is a bond connecting Ar^1 to A at one occurrence and otherwise is hydrogen.

On page 7, please replace line 22 with the following amended line

directly ~~conecting~~connecting Ar^1 and Ar^2.

On page 8, please replace line 2 with the following amended line

III and D is CR^2 where R^2 is Q at one ~~occurence~~occurrence and is a bond connecting Ar^1 to A at one

On page 9, please replace line 31 with the following amended line

wherein one or more of the atoms is ~~labelled~~labeled as a radioisotope of the same element. In a

On page 10, please replace line 3 with the following amended line

Compounds of the invention ~~labelled~~labeled with tritium are useful for the discovery of

On page 10, please replace line 5 with the following amended line

agonism, or antagonism, of the $\alpha 7$ nicotinic acetylcholine receptor. Such tritium-~~labelled~~labeled

On page 14, please replace line 11 with the following amended line

~~occurence~~occurrence of R^2 Q in formula I. In Formula VI E is a halogen or an OSO_2CF_3 group.

On page 18, please replace line 23 with the following amended line

appropriate bis(trialkyltin) in the presence of a suitable ~~orgnometallic~~organometallic catalyst. The

On page 19, please replace line 15 with the following amended line

either be pre-formed or formed *in situ* by including the palladium source and ~~phophine~~phosphine

On page 21, please replace line 9 with the following amended line

the reaction is preferably ~~perfomed~~performed at 100 °C.

On page 22, please replace line 32 with the following amended line

described by Mullen et al. (2000) *J. Med. Chem. 43*, 4045-4050. Radio~~labelled~~labeled forms of

On page 23, please replace lines 3 and 4 with the following amended lines

antagonism, of the α7 nicotinic acetylcholine receptor. Such radio~~labelled~~labeled compounds are synthesized either by incorporating radio~~labelled~~labeled starting materials or, in the case of

On page 24, please replace line 11 with the following amended line

and then filtered, washed with ~~aqueous~~aqueous ammonium hydroxide and evaporated. The residue

On page 45, please replace line 8 with the following amended line

to cool, then quenched with saturated ~~ammoninum~~ammonium diluted with a large amount of

On page 45, please replace line 19 with the following amended line

Example 14 from the reaction of the mixture [[of]] of (*R*)-3'-(4-bromothiazol-2-yl)spiro[1-

On page 57, please replace line 7 with the following amended line

Whatman glass ~~fibre~~fiber filters (thickness C) using a Brandel cell harvester. Pretreating the

New Abstract

An Abstract is enclosed as a separate sheet, which abstract is identical to that of International Application No. PCT/GB2004/002904.